526 related articles for article (PubMed ID: 10152353)
1. Health care reform and the pharmaceutical industry.
Mossinghoff GJ
Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
[TBL] [Abstract][Full Text] [Related]
2. Can price and regulatory controls replace free market competition in the drug industry?
Buc NL; Levitt GM
Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
[No Abstract] [Full Text] [Related]
3. The need for health care reform.
Mossinghoff GJ
Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
[No Abstract] [Full Text] [Related]
4. Eliminating innovation: how price controls limit access.
Ingram J
J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
[No Abstract] [Full Text] [Related]
5. PBMs get new role. Seen as key to drug cost control under new benefit.
Becker C
Mod Healthc; 2003 Dec 22-29; 33(51):31, 33. PubMed ID: 14723089
[No Abstract] [Full Text] [Related]
6. The response to health care reform by the pharmaceutical industry.
Krulwich AS
Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
[No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
[No Abstract] [Full Text] [Related]
8. Does health care reform require killing managed competition?
Telling FW
Clin Perform Qual Health Care; 1994; 2(1):40-1. PubMed ID: 10135443
[No Abstract] [Full Text] [Related]
9. Prescription drug pricing: do competitive forces operate in the pharmaceutical marketplace?
Margolis RE
Healthspan; 1994 Feb; 11(2):9-16. PubMed ID: 10132991
[No Abstract] [Full Text] [Related]
10. National health care reform and a single-payer system: messiah or pariah?
Norato JF
J Health Hum Serv Adm; 1997; 19(3):341-56. PubMed ID: 10168172
[TBL] [Abstract][Full Text] [Related]
11. Clinton's breakthrough drug committee: will it stifle new drug development?
Gatty B
Hosp Formul; 1993 Nov; 28(11):946, 945. PubMed ID: 10130236
[No Abstract] [Full Text] [Related]
12. Universal coverage, drug issues: how do competing health care reform bills compare?
Gatty B
Hosp Formul; 1994 Feb; 29(2):158, 157. PubMed ID: 10131878
[No Abstract] [Full Text] [Related]
13. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
14. Special report. The Ways & Means Health Subcommittee bill: simpler than Clinton ... but plenty of government.
Health Care Reform Week; 1994 Mar; 23(13):suppl 1-4. PubMed ID: 10132955
[No Abstract] [Full Text] [Related]
15. A whole new world?: pharmaceutical responses to the managed care revolution.
Balto DA
Food Drug Law J; 1997; 52(1):83-98. PubMed ID: 10346712
[No Abstract] [Full Text] [Related]
16. Funding pharmaceutical innovation through direct tax credits.
Lybecker KM; Freeman RA
Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
[TBL] [Abstract][Full Text] [Related]
17. Health care reform: pharmaceutical industry sees itself as 'whipping boy'.
Gatty B
Hosp Formul; 1993 Oct; 28(10):872, 871. PubMed ID: 10129137
[No Abstract] [Full Text] [Related]
18. Prescription-drug prices.
Frank RG
N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
[No Abstract] [Full Text] [Related]
19. PBMs come out swinging. Ads say drugmakers are trying to bypass discounts.
Becker C
Mod Healthc; 2004 Nov; 34(47):14. PubMed ID: 15624295
[No Abstract] [Full Text] [Related]
20. Medicare prescription drugs and reform: what the new law will mean to gastroenterologists and their patients.
Fise T
Am J Gastroenterol; 2004 May; 99(5):775-6. PubMed ID: 15128335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
